CompletedPHASE2, PHASE3NCT03692312
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy
Studying Myotonic dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AMO Pharma Limited
- Principal Investigator
- Joseph P Horrigan, MDAMO Pharma
- Intervention
- Tideglusib(drug)
- Enrollment
- 56 enrolled
- Eligibility
- 6-16 years · All sexes
- Timeline
- 2021 – 2023
Study locations (14)
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- University of California, Los Angeles (UCLA), Los Angeles, California, United States
- Stanford University, Palo Alto, California, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- University of Rochester Medical Center, Rochester, New York, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- University of Utah Hospital, Salt Lake City, Utah, United States
- Virginia Commonwealth University - Department of Neurology. Muscular Dystrophy Translational Research Program., Richmond, Virginia, United States
- The Bright Alliance, Randwick, New South Wales, Australia
- Children's Hospital London Health Sciences Centre (LHSC), London, Ontario, Canada
- Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
- New Zealand Clinical Research (NZCR), Auckland, New Zealand
- Newcastle University, Newcastle upon Tyne, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03692312 on ClinicalTrials.govOther trials for Myotonic dystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07486934Efficacy, Safety, and Tolerability of DYNE-101 in Participants With Myotonic Dystrophy Type 1Dyne Therapeutics
- RECRUITINGPHASE2NCT07220603An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)PepGen Inc
- ACTIVE NOT RECRUITINGNCT07493525Fall Frequency and Factors Affecting Dynamic Balance in Patients With Myotonic Dystrophy Type 1Antalya Training and Research Hospital
- RECRUITINGNCT06747884Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy ExtensionVirginia Commonwealth University
- RECRUITINGNCT07385443The Spanish National Registry for Myotonic Dystrophy Type 1Fundació Institut Germans Trias i Pujol
- RECRUITINGNCT07362875Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic DystrophyWake Forest University Health Sciences
- RECRUITINGNANCT06809049Music Intervention for Brain-Heart Disease in Myotonic Dystrophy Type 1 (DM1)Hanns Lochmuller
- RECRUITINGPHASE2NCT06667453A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1PepGen Inc